Physician profile
Ross M Jenson
NPI 1093190415
$19,150.88
in general payments reported to CMS, 2019-2025
37 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,467 · 2020: $2,876 · 2021: $3,048 · 2022: $2,835 · 2023: $3,049 · 2024: $2,727 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925 · Travel and Lodging: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,925.09 |
| Travel and Lodging | $1,999.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,676.17 | 2019-2025 | Eterna, Proclaim, Octrode |
| Medtronic, INC. | $3,275.34 | 2022-2025 | Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $3,198.62 | 2019-2024 | Wavewriter Alpha Prime 16, Na |
| Nevro Corp. | $2,479.41 | 2019-2023 | Senza |
| Relievant Medsystems, INC. | $1,498.69 | 2021-2023 | Intracept |
| Vertos Medical, INC. | $1,352.46 | 2020-2023 | Mild Device Kit |
| Saluda Medical Americas, INC. | $703.55 | 2020-2024 | Evoke Scs, Evoke |
| Abbvie INC. | $332.75 | 2021-2023 | |
| Si-Bone, INC. | $285.26 | 2022-2023 | |
| Spr Therapeutics, INC | $252.89 | 2020-2025 | Sprint Pns System |
| Stryker Corporation | $207.84 | 2021-2022 | |
| Medtronic USA, INC. | $200.31 | 2019-2020 | |
| Amgen INC. | $184.52 | 2020-2023 | Prolia, Evenity |
| Allergan, INC. | $142.55 | 2020-2022 | |
| Nalu Medical, INC. | $140.93 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Flowonix Medical Incorporated | $123.74 | 2020 | |
| Spinal Simplicity, LLC | $122.66 | 2025 | Ha Minuteman G3-R |
| Bioventus LLC | $115.10 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $104.08 | 2024-2025 | |
| Foundation Fusion Solutions, LLC | $93.65 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $84.63 | 2020-2021 | |
| Avanos Medical | $63.94 | 2019 | |
| Pfizer INC. | $59.61 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $58.16 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $57.58 | 2021-2023 | Xtampza |
| Lundbeck LLC | $46.67 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $43.70 | 2020-2021 | |
| Baudax Bio INC. | $31.15 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $30.57 | 2020-2021 | |
| Grt US Holding, INC. | $29.67 | 2022 | |
| Almatica Pharma LLC | $28.74 | 2022-2023 | Gralise |
| Pacira Pharmaceuticals Incorporated | $26.79 | 2025 | Zilretta, Iovera |
| Tersera Therapeutics LLC | $26.36 | 2022 | |
| Upsher-Smith Laboratories LLC | $25.54 | 2021 | |
| Impel Pharmaceuticals INC. | $20.90 | 2023 | Trudhesa |
| Uswm, LLC | $17.43 | 2021 | |
| Stratus Medical, LLC | $8.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$170.16 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Jenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.